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Summary
 
Autoimmune mediated destruction of 
 
b
 
 cells of the islets of Langerhans leads to insulin-depen-
dent diabetes mellitus (IDDM). Rat insulin promoter (RIP) lymphocytic choriomeningitis vi-
rus (LCMV) transgenic mice that express the nucleoprotein (NP) or glycoprotein (GP) of
LCMV under control of the RIP in their 
 
b
 
 cells develop IDDM after infection with LCMV
and serve as a model for virus-induced IDDM. Recently, Kagi et al. (Kagi, D., B. Odermatt, P.
Ohashi, R.M. Zinkernagel, and H. Hengartner. 1996. 
 
J. Exp. Med.
 
 183:2143–2149) showed,
using RIP LCMV perforin-deficient mice, that IDDM does not occur in the absence of per-
forin. They concluded that perforin-mediated killing by cytotoxic T lymphocytes (CTLs) is
the main factor needed for 
 
b
 
 cell injury and destruction. Here we provide evidence that killing
of 
 
b
 
 cells is more complex and multifactorial. By the use of our RIP LCMV model, we show
that in perforin competent but interferon-
 
g
 
 (IFN-
 
g
 
)–deficient mice, 
 
b
 
 cell injury is limited and
IDDM does not occur. For these studies, double transgenic mice were generated that were ge-
netically deficient in the production of IFN-
 
g
 
 and express LCMV NP or GP in their 
 
b
 
 cells. In
such mice, IDDM was aborted despite the generation of LCMV-specific antiself CTLs that dis-
played normal cytolytic activity in vitro and in vivo and entered the pancreas. However,
mononuclear infiltration into the islets did not occur, and upregulation of class I and II mole-
cules usually found in islets of RIP LCMV single transgenic mice after LCMV infection pre-
ceding the onset of clinical IDDM was not present in these bigenic mice. Our findings indicate
that in addition to perforin, 
 
b
 
 cell destruction, development of insulitis, and IDDM also de-
pend on the cytokine INF-
 
g
 
, presumably through enhancement of major histocompatibility
complex expression and antigen presentation.
 
D
 
estruction of the insulin-producing 
 
b
 
 cells located in
the islets of Langerhans leads to insulin-dependent di-
abetes mellitus (IDDM)
 
1
 
 (1–3). Host genes, T cell autoim-
mune responses (4), cytokines (5) and viruses (2, 6) have been
implicated in the initiation and progression of this disease
(8–14). Immune responses including autoimmune reactions
are believed to be regulated by a balance of Th
 
1
 
 (inflamma-
tory) and Th
 
2
 
 (regulatory) cytokines (5, 15–18). IFN-
 
g
 
 is a
Th
 
1
 
-type cytokine that plays an intricate role in antiviral
host defense mechanisms, activation of CTLs, and enhance-
ment of inflammatory reactions (18–24). Expression of IFN-
 
g
 
under control of the rat insulin promoter (RIP) in trans-
genic mice leads to MHC upregulation, inflammation, and
IDDM (11, 22). When expressed in 
 
b
 
 cells of transgenic
mice together with viral antigen, it leads to spontaneous de-
velopment of autoimmune diabetes with generation of an-
tiself (viral) CTLs in the absence of viral challenge (12).
We and others have created transgenic (tg) mouse mod-
els to dissect the role(s) played by various components of the
immune system leading to IDDM (6, 8, 25). tg mice ex-
pressing a viral (“self”) nucleoprotein (NP) or glycoprotein
(GP) gene of lymphocytic choriomeningitis virus (LCMV) in
pancreatic 
 
b
 
 cells under control of the RIP fail to develop
IDDM spontaneously (defined as hyperglycemia, hypoin-
sulinemia, mononuclear infiltration into and destruction of
the islets of Langerhans) even over a 15-mo observation
period (6). However, these mice are not tolerant to the
transgene. First, peripheral lymphocytes from these trans-
genic mice can be primed in vitro to generate primary anti-
LCMV CTLs after incubation with 
 
Drosophila
 
 cells express-
ing MHC class I molecules and the appropriate LCMV
peptide (26). Second, upon infection with LCMV, 
 
.
 
95%
develop IDDM due to the generation of an antiviral (anti-
self) CD8
 
1
 
 CTL response. Studies including adoptive trans-
fer of CD8
 
1
 
 cells recovered from islets, immunochemical
depletion, and use of CD8 knockout mice indicate that
 
1
 
Abbreviations used in this paper:
 
 ARM, Armstrong; GP, glycoprotein;
IDDM, insulin-dependent diabetes mellitus; LCMV, lymphocytic chori-
omeningitis virus; NOD, nonobese diabetic; NP, nucleoprotein; RIP, rat
insulin promoter; tg, transgenic.
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these effector CTL are responsible for initiating the process
leading to selective and progressive damage of pancreatic 
 
b
 
cells and IDDM (6, 25).
RIP LCMV transgenic mice that express the viral trans-
gene in the pancreas and in the thymus delete high affinity,
but not low affinity, antiself CTLs and, as a consequence,
develop slow-onset IDDM that depends on both CD4
 
1
 
and CD8
 
1
 
 lymphocytes (25, 27). In contrast, RIP-LCMV
transgenic mice that express the viral antigen only in the
pancreas, develop a rapid-onset IDDM (2 wk) that depends
solely on the action of antiself CD8
 
1
 
 CTL.
CTL have been implicated as effector cells in other mod-
els of IDDM and in human IDDM. For example, studies
with nonobese diabetic (NOD) mice showed that IDDM
can be transferred by CD8
 
1
 
 T cells (28, 29). More recently
it has been proposed that specific MHC-restricted killing of
 
b
 
 cells could be the initiating event for IDDM (14), and
glutaric acid decarboxylase and insulin-specific CTLs were
isolated from NOD mice (30, 31). CTLs kill target cells by
a MHC-restricted mechanism involving the recognition of
specific peptides presented to the TCR by MHC class I
glycoproteins. Killing is mediated by the release of cyto-
toxic granules containing perforin (32, 33) or by the per-
forin-independent FAS pathway (35). Recently, Kagi et al.
showed that killing of 
 
b
 
-cells by CTLs is dependent on the
release of perforin, since RIP LCMV transgenic mice with
a disrupted perforin gene were unable to develop IDDM
after LCMV infection (34).
We questioned whether cytokines, especially IFN-
 
g
 
,
might also play a role in 
 
b
 
 cell destruction and IDDM. To
explore the role of IFN-
 
g
 
, we generated tg mice that ex-
pressed the LCMV viral (“self”) transgene in 
 
b
 
 cells in the
islets of Langerhans and were either competent or geneti-
cally deficient in the production of IFN-
 
g
 
 (RIP LCMV
IFN-
 
g
 
 
 
1
 
/
 
1
 
 or 
 
2
 
/
 
2
 
 mice). This allowed us to determine
whether 
 
b
 
 cells can be directly destroyed by antiself CTLs
in the absence of IFN-
 
g
 
. Here we report that despite the
generation of high or low affinity autoreactive CTLs, IDDM
did not occur in IFN-
 
g
 
 deficient RIP LCMV transgenic
mice. Antiself (viral) CTLs trafficked to the pancreas and
were found around the islets. However, neither infiltration
into the islets nor upregulation of MHC class I or class II
molecules occurred. We conclude that IFN-
 
g
 
 is a key fac-
tor required for the induction and maintenance of the au-
toimmune destruction of 
 
b
 
 cells in the islets of Langerhans
that leads to IDDM.
 
Materials and Methods
 
Transgenic Mouse Lines.
 
Generation and characterization of RIP
LCMV tg mice with rapid (8–14 d)- or slow-onset (1–6 mo)
IDDM after LCMV infection has been described (25). For rapid
onset we chose the RIP GP 34-20 (H-2
 
b
 
) tg line as a prototype.
These mice express the viral transgene in the pancreas, but not in
the thymus. For the slow-onset IDDM paradigm, the RIP NP
25-3 (H-2
 
d
 
) tg line was selected. RIP NP 25-3 mice express the
viral NP in both the pancreas and the thymus, but do not express
it in any other tissues (25).
Mice with a nonfunctional IFN-
 
g
 
 gene were generated by T.
Stewart and his colleagues (23) by replacing the normal IFN-
 
g
 
 al-
lele in mouse embryonic stem cells with a defective allele.
C57Bl/6 (H-2
 
b
 
) and BALB/c (H-2
 
d
 
) IFN-
 
g
 
–deficient mice were
obtained from Genentech Inc. (South San Francisco, CA). Mice
homozygous for the mutation in the IFN-
 
g
 
 gene (IFN-
 
g
 
–defi-
cient or 
 
2
 
/
 
2
 
 mice) were housed in specific, pathogen-free con-
ditions, were healthy, fertile, had normal life spans, and did not
spontaneously develop IDDM.
Double tg mice that express LCMV NP or GP protein in their
pancreas and are IFN-
 
g
 
–deficient were obtained by crossing
IFN-
 
g
 
–deficient mice with RIP LCMV tg mice, and then back-
crossing the LCMV-positive littermates from the F1 generation,
which are heterozygous for the IFN-
 
g
 
 gene mutation to IFN-
 
g
 
-deficient mice. As a result, IFN-
 
g
 
-deficient (
 
2
 
/
 
2
 
) and IFN-
 
g
 
(
 
1
 
/
 
1
 
) mice were obtained that did or did not express LCMV
proteins in their pancreas. These mice were used in experimental
and control groups. For further studies, the LCMV positive F1
littermates from the first mating were backcrossed for five genera-
tions to the RIP LCMV (IFN-
 
g
 
 
 
1
 
/
 
1
 
) background and the re-
sulting LCMV-positive littermates that were heterozygous for
IFN-
 
g
 
 were intercrossed once to generate RIP LCMV IFN-
 
g
2
 
/
 
2
 
 and 
 
1
 
/
 
2
 
, or 
 
1
 
/
 
1
 
 mice for use in experiments. This back-
cross was necessary to ensure that no IDDM-protective genes
were linked to the IFN-
 
g
 
 
 
2
 
/
 
2
 
 genetic background.
 
Biochemical Studies.
 
Transgenic mice were identified by hy-
bridization of DNA extracted from tail biopsies using an LCMV
NP- or GP-specific probe (6). RNA was extracted from PBL and
organs (thymus, brain, liver, muscle) by the Guanidinium-Iso-
thiocyanate method (25) for analysis. Before PCR analysis, RNA
was treated with RNAse-free RQ1 DNAse to eliminate contam-
inating the DNA. The reverse transcriptase-PCR was carried out
for 40 cycles. LCMV NP-specific primers used were: 5
 
9
 
 CAG
TTA TAG GTG CTC TTC CGC 3
 
9
 
 and 5
 
9
 
 AGA TCT GGG
AGC CTT GCT TTG 3
 
9
 
. Heterozygosity or homozogosity for
the IFN-
 
g
 
 knockout defect was also tested for by PCR. The wild-
type IFN-
 
g
 
 gene was detected using primers AGAAGTAAGTG-
GAAGGGCCCAGAAG and AGGGAAACTGGGAGAGGAG-
AAATAT that resulted in a 220-bp product while the mutant
gene was detected with primers TCAGCGCAGGGGCGCCCG-
GTTCTTT and ATCGACAAGACCGGCTTCCATCCGA that
defined a 190-bp product (23, 25).
 
Virus.
 
The virus used was LCMV Armstrong (ARM), clone
53b. Its origin, quantitation by plaquing, sequence, and biological
properties have been described (36–38).
 
CTL Assay.
 
CTL activity was recorded in a 5–6 h in vitro
 
51
 
Cr release assay (6, 25, 39–41). Samples were run in triplicate
and variance was 
 
,
 
10%. To judge CTL activity, uninfected or
infected targets with either LCMV ARM (multiplicity of infec-
tion 1), vaccinia virus expressing LCMV NP, or LCMV GP (mul-
tiplicity of infection 3) were used. Target cells were H-2
 
b
 
 (MC57)
or H-2
 
d
 
 (BALB Cl7) fibroblasts. Lymphocytes were obtained from
spleens of 8–12-wk-old mice either not inoculated or given 2 
 
3
 
10
 
3
 
 PFU of LCMV ARM intraperitoneally 7 d earlier. Single-cell
suspensions were made and used at 50:1, 25:1, and 12:1 effector/
target ratios. H-2
 
b
 
- and H-2
 
d
 
- restricted LCMV-specific CTL
clones (42) were used at effector/target ratios of 10:1, 5:1, and 1:1.
Other secondary CTL lines and clones were generated and
cloned by limiting dilution (42). For coating with peptides, target
cells were preincubated with the respective peptide at 50 
 
m
 
g/well
for 30 min before starting the 4–5 h incubation for the 
 
51
 
Cr re-
lease assay.
 
Recovery of CTL from Pancreas.
 
CTLs were isolated from the 
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pancreas as described (26). Briefly, pancreatic tissues obtained from
tg mice were freed from fat and other tissues, digested with colla-
genase, and lymphoid cells were recovered by centrifugation through
a ficoll-hypaque gradient.
 
Analysis of IDDM.
 
IDDM was defined by hyperglycemia (blood
glucose . 300 mg/dl), low levels of pancreatic insulin (,10 mg of
insulin/mg of pancreas), and presence of a mononuclear cell infil-
tration in the islets. Blood samples were obtained from the retro-
orbital plexus of mice at weekly or monthly intervals. Amount of
glucose in the blood was determined using Accucheck II strips
(Boehringer Mannheim, Indianapolis, IN). Normal blood glucose
for age- and sex-matched control was mean 61 SE (20–40 mice/
group) 145 6 7. Insulin concentration in the pancreas was deter-
mined by radioimmune assay (6) and normal levels of insulin were
40 mg/mg 6 12. Absence or presence of mononuclear cells in the
islets was studied in tissues fixed in 10% zinc formalin, mounted
in paraffin, and stained with hematoxylin and eosin (25).
Immunohistochemical Analyses of Tissues. Tissues were quick fro-
zen in O.C.T. compound, 6–10-mm cryomicrotome sections ob-
tained, fixed for 1 min in 1% paraformaldehyde, washed in PBS,
and incubated with avidin/biotin to remove nonspecific binding.
Primary antibodies consisting of rat anti–mouse CD4 (clone RM
4-5), anti-CD8 (clone 53-6.7), anti-B220 (clone RA3 6B2), anti-
F4/80 (clone A3-1), anti–MAC-1 (clone M 1/70), anti–class I
(clone M 1/42), and anti–class II (clone M5/114), (PharMingen,
San Diego, CA and Boehringer Mannheim) were applied for 1 h.
After washing, secondary antibody [biotinylated goat anti–rat (or
anti–mouse) IgG (Vector Laboratories, Inc., Burlingham, CA)] was
added for 1 h. Color reaction was obtained with avidin-peroxi-
dase conjugate (Boehringer Mannheim) and diaminobenzidine in
the presence of H2O2 (43).
ELISA Assay for IFN-g. Sandwich ELISA assays for IFN-g
production were carried out as recommended by PharMingen (San
Diego, CA), who also provided matched pairs of capture and detec-
tion antibodies. Tissue culture supernatants tested in the ELISA
were harvested after 3 d in vitro culture of 105 splenocytes ob-
tained 7 d after LCMV infection and cultured in 10% RPMI con-
taining 1025 M LCMV NP H-2d CTL peptide (RPQASGVYM).
Results
RIP LCMV (NP or GP) 3 IFN-g-deficient tg mice generate
antiself (virus) CTLs After Infection with LCMV. As shown
in Table 1, RIP LCMV transgenic mice with a competent
or dysfunctional IFN-g gene generated good levels of
H-2b- or H-2d-restricted primary CTLs after LCMV infec-
tion. Note that, as reported previously (25), RIP NP mice
Table 1. Primary CTL Levels Found in RIP LCMV IFN-g–deficient or –competent Mice
Effector
day 7 splenocytes
Specific 51Cr release (%) from targets
H-2d H-2b
Group E/T LCMV vv/GP NPpep log pe* LCMV vv/GP
H-2d 50:1 78 6 62  6  1 39 6 12 2900
IFN-g–competent 25:1 58 6 9 0 36 6 60 0
H-2d 50:1 55  6 12 2 6 1 39 6 8 2900
IFN-g–deficient 25:1 38 6 11 0 29 6 30 0
RIP–NP, H-2d 50:1 28 6 7 11 6 4 20 6 4 2700
IFN-g–competent 25:1 15 6 43  6  2 15 6 30 0
RIP–NP, H-2d 50:1 22 6 7 12 6 5 19 6 3 2700
IFN-g–deficient 25:1 8 6 44  6  4 11 6 40 0
H-2b 50:1 0 0 0 55  6 9 33 6 7
IFN-g–competent 25:1 0 0 0 28 6 6 16 6 6
H-2b 50:1 0 0 0 60 6 9 32 6 7
IFN-g–deficient 25:1 0 0 0 33 6 5 20 6 2
RIP GP, H-2b 50:1 0 0 0 52 6 4 36 6 7
IFN-g–competent 25:1 0 0 0 22 6 3 15 6 5
RIP GP, H-2b 50:1 0 0 0 60 6 6 28 6 8
IFN-g–deficient 25:1 0 0 0 38 6 5 22 6 8
CTL assays were performed as described in the Materials and Methods section. Target cells were BALB/C17 (H-2d) fibroblasts uninfected or in-
fected with LCMV (ARM), or vaccinia viruses expressing the complete LCMV GP (vv/GP). Background lysis of uninfected cells was ,5% in all as-
says and was subtracted from the lysis (51Cr release) values shown. Five mice were tested per group and the mean 1/2 1 SE is displayed. Primary
CTL activity found in spleens was assessed on day 7 after LCMV infection. Affinities of antiself CTLs (*) were recorded according to the minimal
concentration of LCMV-NP peptide (RPQASGVYM) required for lysis of target cells by CTLs. Note that high affinity CTLs found in non-tg mice
require 2 logs less peptide for lysing target cells than low-affinity CTLs found in tg mice (27). Further, low affinity CTLs required 10 times less anti-
CD8 antibody to inhibit CTL killing by 50% (C50 [aCD8]) than high affinity CTLs from non-tg mice.534 Role of IFN-g in Virus-induced (Type 1) Diabetes and b Cell Destruction
who express the viral transgene in the thymus have a spe-
cific reduction in their LCMV NP–specific CTL activities
due to negative thymic selection of high affinity CTLs.
CTL activity, however, is not completely aborted, since low
affinity CTLs escape the negative selection process and are
found in the periphery (6, 27). Affinity was assessed by
using log dilutions of LCMV NP peptide H-2d-restricted
aa118-126 (RPQASGVYM) to coat target cells in the CTL
assay (Table 1). These low affinity CTLs are able to induce
slow-onset IDDM in single tg RIP NP mice (6). RIP GP
tg mice used as a model for fast-onset IDDM do not ex-
press the transgene in the thymus and generate high affinity
primary CTLs in the presence and absence of IFN-g after
LCMV infection (Table 1).
In the Absence of IFN-g, Virus-induced Diabetes Does Not
Occur in RIP LCMV tg Mice. IDDM did not occur in
RIP GP or NP 25-3 single tg mice unless they were chal-
lenged with LCMV ARM (Fig. 1). Fig. 1 also shows that
2–8 wk after receiving 1 3 105 PFU of LCMV intraperito-
neally, most IFN-g–competent RIP GP (fast-onset IDDM)
or NP (slow-onset IDDM) single tg mice develop IDDM.
In contrast, virus-inoculated double tg mice (10 mice/group)
that were deficient in IFN-g production did not develop
IDDM over a 5–8-mo observation period. Thus, virus in-
duced IDDM does not occur in the absence of IFN-g, re-
gardless of the affinity of the generated antiself (viral) CTLs.
Incidence of IDDM was reduced and delayed in RIP
LCMV IFN-g (1/2) mice. To ensure that the lack of
IDDM in the absence of IFN-g was not due to the effect
of a potential protective gene linked to the IFN-g (2/2)
background, the experiment was repeated using tg mice
that were backcrossed to the RIP LCMV (IFN-g 1/1)
background for five generations (see Materials and Meth-
ods section for breeding scheme). This backcross for five
generations makes an IDDM-protective effect conferred by
genes accidentally linked to the IFN-g (2/2) mutation
statistically unlikely (44). Fig. 1 shows that even after the
backcross, the incidence of IDDM in IFN-g (1/2) RIP
LCMV littermates was still reduced. These findings made
the influence of an IDDM-protective gene linked to the
IFN-g knockout genotype not likely. To address the possi-
bility that an IFN-g gene dose related effect influenced the
kinetics of IDDM, we compared the levels of IFN-g pro-
duced by lymphocytes from RIP LCMV 3 IFN-g (1/1),
(1/2), and (2/2) littermates. The results indicated that
the lower incidence of IDDM observed in RIP LCMV
IFN-g ( 1 / 2 ) littermates is due to a relatively lower
amount of IFN-g production. Levels of IFN-g detected in
the supernatant of splenocytes harvested 7 d after LCMV
infection and stimulated for 3 d in the presence of LCMV
H-2d (NP) peptide were 2000 6 400 U/ml for IFN-g
(1/1), 700 6 320 U/ml for IFN-g (1/2), and nonde-
tectable for IFN-g (2/2) littermates.
Immunohistochemical Analysis of Islets from RIP LCMV 3
IFN-g–deficient or Competent tg Mice. Immunohistochemi-
cal analysis of islets from RIP LCMV 3 IFN-g–deficient
or –competent tg mice was carried out 45 d after infection
with LCMV. Results are shown in Fig. 2. In the absence of
IFN-g, insulitis was markedly reduced (Fig. 2, C versus B).
IFN-g–deficient mice failed to show infiltration into the is-
lets, while islets from IFN-g–competent RIP LCMV mice
showed insulitis and destruction of most b cells. Further,
CD81 CTLs were found in infiltrates of single tg RIP
LCMV IFN-g–competent mice as expected (Fig. 2 E, 25).
In contrast, CTL were absent in islets of IFN-g–deficient
mice, but were found in the pancreas or around the islets
(Table 2; Fig. 2 I). Thus, despite generation of antiviral
CTLs (Table 1) that can enter the pancreas, b cells were
not destroyed in IFN-g–deficient mice. CTLs were seen
passing through the pancreas, but were not retained in, or
Figure 1. Incidence of IDDM
(blood glucose .300 mg/dl) in
RIP LCMV (NP or GP) IFN-g–
deficient or –competent tg mice.
Blood glucose levels were mea-
sured at 2-wk intervals as described
in Materials and Methods, 10
mice per group were analyzed.
LCMV-treated mice were chal-
lenged with 2 3 103 PFU
LCMV intraperitoneally.535 von Herrath and Oldstone
infiltrated into, the islets (Fig. 2 F). Lastly, MHC class I
(Fig. 2, H and I) expression was upregulated in inflamma-
tory islet lesions and on b cells of RIP LCMV tg mice (Fig.
2 H). In contrast, upregulation of class I (Fig. 2 I) molecules
did not occur in IFN-g–deficient RIP LCMV mice and
b cells remained intact. As shown in Fig. 2, A, D, and G,
these events were not observed in non-tg mice infected
with LCMV. Further studies showed that expression of
MHC class II that is usually elevated in islets of tg mice
with IDDM, was not detected in islets of IFN-g (2/2)
mice (data not shown).
IFN-g–deficient RIP LCMV tg Mice have less LCMV-spe-
cific Memory CTLs in the Pancreas than their IFN-g–Competent
Littermates. Levels of LCMV-specific memory CTLs were
quantitated in RIP LCMV IFN-g–competent or –deficient
mice. The results are shown in Table 2. Normal and IFN-
g–deficient mice or RIP LCMV tg IFN-g–competent or
–deficient mice generated nearly equivalent amounts of
LCMV-specific memory CTLs in their spleens (precursor
frequency average 1/1,500). However, fewer LCMV-spe-
cific CTLs were detected in the pancreas of RIP LCMV
IFN-g–deficient mice that had not developed IDDM com-
pared to LCMV-specific CTLs recovered from pancreas of
IFN-g–competent RIP LCMV mice that had developed
IDDM (Table 2).
Discussion
The major finding documented here is that injury to
b cells mediated by CTLs does not occur in the absence of
IFN-g (Fig. 1). Further, IFN-g is not required for the gen-
eration of LCMV-specific CTLs (Table 1) and killing of
Figure 2. Histopathology and immunochemical analysis of islets of Langerhans in LCMV-infected RIP LCMV (NP) IFN-g–deficient or –competent
tg mice. Immunohistochemical staining of consecutive 5-6 micron sections of islets was carried out as described in Materials and Methods. At least three
different areas were surveyed per mouse. 10 mice were studied from each experimental group. Representative sections are shown that were similar for
each mouse in that particular group. Sections shown were processed and stained at the same time. Original magnification is 200. Panels A–F indicate tg
mouse strain, time after infection, and staining method applied.536 Role of IFN-g in Virus-induced (Type 1) Diabetes and b Cell Destruction
target cells in vitro, and clearance of acute LCMV infection
in vivo can occur in the absence of IFN-g (21). Thus,
CTLs generated in IFN-g-deficient mice can lyse target
cells in vitro, clear virus infections in vivo, and enter the
pancreas in vivo (Fig. 2). A likely mechanism for the abla-
tion of the autoimmune process and the failure of IDDM
to occur in the absence of IFN-g is the insufficient upregu-
lation of MHC class I molecules on b cells and class II mol-
ecules on APCs, but not a defect in CTL generation or
function. As a consequence, there is a lack of antigen pre-
sentation and functional CTLs are not retained in the islets.
These findings provide a clear rationale for suppressing in-
flammatory cytokine levels like IFN-g locally in the islets
as a treatment of IDDM.
IFN-g is a key cytokine produced by activated CTLs. It
is involved in the upregulation of MHC molecules and in
antiviral host defense (21, 45–47). Recent data show that
IFN-g knockout mice generate LCMV-specific primary
and memory CTLs with equivalent activities as found in
non-tg littermates (21). The generation of LCMV-specific
primary CTLs in IFN-g–deficient mice terminates an acute
LCMV viral infection (21). However, when memory CTLs
from IFN-g knockout mice are adoptively transferred into
persistently infected recipients, they are unable to clear the
virus showing that, while IFN-g is not required for CTL
activity in vitro or control of acute infection in vivo, it is
required for viral clearance of a persistent infection by
CTLs in vivo (22, 45, 46). The role IFN-g plays in IDDM
is likely mediated by the upregulation of MHC molecules
on b cells and APCs in the islets. First, upregulation of
MHC class I glycoproteins is a frequent marker during the
development of IDDM (11, 26). Second, IDDM does not
occur in the absence of MHC class I expression on b cells
(25). For example, expression of the adenoviral E3 gene
complex can prevent MHC class I trafficking to the cell
surface. When the E3 complex is co-expressed with LCMV
proteins under the RIP in b cells, upregulation of MHC
class I Db molecules is suppressed specifically and IDDM is
prevented (von Herrath, M., S. Efrat, M. Oldstone, and M.
Horwitz, manuscript submitted for publication). However,
upregulation of MHC expression itself in the absence of a
specific (viral) trigger or in the absence of autoreactive CTLs
is not sufficient for the development of IDDM (43). Fur-
ther, APCs expressing MHC class II are not found in islets
of RIP LCMV IFN-g (2/2) mice (data not shown) indi-
cating that the lack of IFN-g also results in a loss of infiltra-
tion by APCs that are required to propagate the autoim-
mune process leading to IDDM.
IFN-g could also contribute to the autoimmune process
in the pancreas by “bystander” activation of autoreactive
CTLs and other inflammatory cells (48). The recovery of
lower numbers of antiself (viral) CTLs from the pancreas of
IFN-g–deficient RIP LCMV mice 60 d after infection
(Table 2) suggests that this may also occur. Hence, both
upregulation of MHC molecules and “bystander” activa-
tion may be needed for IDDM to develop.
Recently, Kagi et al. reported that IDDM did not occur
in perforin–deficient RIP LCMV transgenic mice and con-
cluded that b cell destruction was predominantly a conse-
quence of perforin-mediated lysis by antiself (viral) CTLs
(34). In this model, virus-induced MHC class I restricted
CTLs are the key factor for the induction of IDDM. Dia-
betes does not occur in the absence of MHC class I expres-
sion on b cells (25) or the absence of CD81 CTLs (8, 25).
Both our own (Tishon, T., and M.B.A. Oldstone, unpub-
lished data) and other results (49) indicate that while perforin-
competent CTLs are required to lyse target cells in vitro,
they are unable to destroy b cells in vivo in the absence of
IFN-g to cause IDDM (Fig. 1). Thus, the cytokine IFN-g
plays an important role in the pathogenesis of IDDM and
Table 2. INF-g–deficient RIP LCMV tg Mice Have Fewer LCMV-specific Memory CTLs in the Pancreas than their
IFN-g–competent Littermates
Precursor frequency of CTL
Killing of 
H-2d targets Secondary effector day 60 CTL H-2d H-2b
Group Origin LCMV vv/GP NPpep LCMV LCMV
H-2d IFN-g–competent Spleen 1/1,500 NDT 1/2,500 NDT 60 6 7%
H-2d IFN-g–deficient Spleen 1/3,000 NDT 1/4,200 NDT 54 6 9%
RIP NP, H-2d IFN-g–competent Spleen 1/3,000 1/9,000 1/3,900 NDT 34 6 8%
RIP NP, H-2d IFN-g–deficient Spleen 1/5,000 1/9,000 1/7,000 NDT 35 6 2%
RIP NP, IDDM IFN-g–competent Pancreas 1/2,000 not done 1/6,000 NDT 38 6 7%
RIP NP, no IDDM g-IFN–deficient Pancreas 1/20,000 NDT NDT NDT 18 6 5%
Secondary CTLs were recovered from spleens and pancreata of infected (103 PFU LCMV intraperitoneally) IFN-g–deficient RIP LCMV mice, sin-
gle transgenic RIP LCMV mice, and nontransgenic IFN-g–deficient or –competent controls. CTL activity was tested on syngeneic LCMV infected
or uninfected target cells after a 5–14 d in vitro stimulation (see Materials and Methods), and precursor frequency analysis was performed as described
(26). NDT, not detectable (,1/60,000).537 von Herrath and Oldstone
without it, IDDM does not occur, even after an 8-mo ob-
servation period. Kagi et al (34) reported infiltration and
retention of CD81 lymphocytes in the islets was observed
in the absence of perforin although IDDM did not occur
over the 2-mo observation period after LCMV infection.
Whether IDDM could have occurred at later times in the ab-
sence of perforin and in the presence of IFN-g is unknown.
It has been reported (24) that IDDM is delayed, but not
aborted, in NOD mice in the absence of IFN-g. A likely
reason why IDDM occurs in IFN-g–deficient NOD mice,
but fails to occur in the RIP LCMV tg model, is that NOD
mice are usually genetically prone to spontaneously de-
velop IDDM (50). They express genes that convey suscepti-
bility to IDDM, and it is likely that their b cells are more
sensitive to destruction. By contrast the RIP LCMV tg
mice do not spontaneously develop diabetes (6), even after
a 2-yr observation period (Tishon, T., and M.B.A. Old-
stone, unpublished data).
From our data, it is unlikely that the lack of IDDM in
IFN-g (2/2) and the lower incidence of IDDM in IFN-g
(1/2) mice is due to an IDDM-protective gene linked to
the IFN-g (2/2) mutation for several reasons. First, simi-
lar kinetics of IDDM are observed in all groups of mice in-
dependent of whether F-1 backcrosses to IFN-g (2/2)
background or F-5 backcrosses to the RIP LCMV back-
ground are used (Fig. 1). Second, recent work by Kra-
kowski et al. (51) demonstrated a protective effect of the
IFN-g (1/1) genotype for experimental allergic encepha-
litis (EAE), whereas the encephalitis was enhanced on the
IFN-g (2/2) background. Such findings were not mir-
rored in our report. Finally, and most importantly, we find
less IFN-g production by splenocytes from IFN-g (1/2)
compared to IFN-g (1/1) splenocytes. This finding cor-
relates with the lower incidence of IDDM in IFN-g (1/2)
mice and suggests a quantitative gene-dosage effect in IFN-g
production as the explanation for the different incidence of
IDDM observed in RIP LCMV IFN-g (1/1) and (1/2)
mice.
In conclusion, a multifactorial process leads to IDDM
and autoimmune destruction of b cells. The development
of insulitis involves a cascade of events. Generation of anti-
self islet-antigen–specific CTLs, a functional perforin path-
way, the presence of IFN-g, upregulation of MHC class I
on b cells, and likely the presence of CD4 lymphocytes are
required. Identification of the factors involved will suggest
the strategies that can be applied to hinder or prevent the
autoimmune process from continuing and hopefully pre-
vent IDDM.
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